文献速递炎症性肠病

小分子中性粒细胞调节剂ADS051在1期单次递增剂量研究中安全且耐受性良好

Small-Molecule Neutrophil Modulator ADS051 is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study.
PubMed 文献 · Am J Gastroenterol · 2024-11-26

本研究为1期单次递增剂量研究,50名健康成人按4:1随机分入5个递增剂量队列,单次口服ADS051 100 mg、300 mg、700 mg、1,500 mg、3,500 mg或安慰剂,随访至给药后30天。ADS051安全且耐受性良好,粪便中回收剂量累积平均为10%-24%,血液中仅2/440份样本可定量,尿排泄平均<0.035%。作者认为ADS051可能成为治疗溃疡性结肠炎的安全有效的局部作用中性粒细胞靶向药物。

要点

  • 50名健康成人随机接受单次口服ADS051 100-3,500 mg或安慰剂,随访至给药后30天。
  • ADS051安全且耐受性良好,无严重不良事件,无因不良事件停药。
  • 粪便中回收剂量累积平均10%-24%,血液仅2/440份样本可定量,尿排泄平均<0.035%。

核心结论

  • ADS051安全、耐受性良好,在粪便中达到高浓度且全身暴露极低。
  • 作者认为ADS051可能成为治疗溃疡性结肠炎的安全有效的局部作用中性粒细胞靶向药物。

研究设计与样本

  • 1期单次递增剂量研究,纳入50名健康成人,按4:1随机分入5个递增剂量队列。
  • 单次口服ADS051 100 mg、300 mg、700 mg、1,500 mg、3,500 mg或安慰剂,随访至给药后30天。
  • 评估ADS051在粪便、血液和尿液中的安全性和药代动力学。

主要发现

  • ADS051安全且耐受性良好,无严重不良事件报告,无因不良事件停药。
  • ADS051 1,500 mg组有2名参与者(5.0%)报告便秘不良事件,安慰剂组无。
  • 所有剂量组中,粪便中回收的ADS051剂量累积平均为10%-24%,大多在给药后48小时内。
  • 440份血液样本中仅2份可定量ADS051(7.64和69.8 ng/mL)。
  • 平均<0.035%的ADS051剂量经尿液排泄。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A need for better treatment options for moderate to severe ulcerative colitis (UC) persists because of the efficacy and safety limitations of current therapies. Neutrophil epithelial transmigration is associated with the characteristic colonic mucosal inflammation in and very likely involved with the pathogenesis and clinical symptoms of UC. ADS051 is a small-molecule inhibiting neutrophil migration and activation, which are potentially important therapeutic targets in UC. The phase 1 single ascending dose study evaluated ADS051's safety, tolerability, and pharmacokinetics in healthy volunteers. METHODS: Fifty healthy adults were randomized 4:1 into 5 ascending dose cohorts to receive a single oral dose of ADS051 100 mg, 300 mg, 700 mg, 1,500 mg, 3,500 mg, or placebo. Participants were followed until 30 days after dosing. Safety and pharmacokinetics of ADS051 in stool, blood, and urine were evaluated. RESULTS: ADS051 was safe and well-tolerated. Adverse events (AEs) of constipation were reported by 2 participants (5.0%) in the ADS051 1,500 mg group vs none in the placebo group. No serious AEs reported and no discontinuations due to AEs. In all dose groups, a cumulative average of 10%-24% of the ADS051 dose was recovered in stool, mostly within 48 hours after dosing. ADS051 was quantifiable in only 2 of 440 blood samples (7.64 and 69.8 ng/mL). On average, <0.035% of the ADS051 dose was excreted in urine. DISCUSSION: ADS051 was safe, well-tolerated, and achieved high stool concentrations with minimal systemic exposure. ADS051 could be a safe and effective, locally acting, neutrophil-targeting agent for the treatment of UC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Cheifetz AS, Allegretti JR, Quintas M, et al. Small-Molecule Neutrophil Modulator ADS051 is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study. Am J Gastroenterol. 2024. PMID: 39588987. doi:10.14309/ajg.0000000000003237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。